Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Revenue (2016 - 2025)

Editas Medicine (EDIT) has disclosed Revenue for 11 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 12265.57% to $7.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.4 million, a 24.9% decrease, with the full-year FY2024 number at $32.3 million, down 58.64% from a year prior.
  • Revenue was $7.5 million for Q3 2025 at Editas Medicine, up from $3.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $60.0 million in Q4 2023 to a low of $42000.0 in Q3 2022.
  • A 5-year average of $9.0 million and a median of $6.2 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 99.32% in 2022, then skyrocketed 12604.76% in 2023.
  • Editas Medicine's Revenue stood at $12.5 million in 2021, then crashed by 47.58% to $6.5 million in 2022, then skyrocketed by 818.74% to $60.0 million in 2023, then plummeted by 49.03% to $30.6 million in 2024, then plummeted by 75.35% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Revenue are $7.5 million (Q3 2025), $3.6 million (Q2 2025), and $4.7 million (Q1 2025).